Trevena
TRVN
$0.39
Share price
-4.40%
Change (1 day)
-39.85%
Change (1 year)
Categories
Trevena (TRVN) - Total liabilities
Total liabilities on the balance sheet as of September 2023 : $41.58 M
According to Trevena's latest financial reports the company's total liabilities are $41.58 M. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Trevena - Total liabilities on balance sheet (from 2012 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $33.08 M | 113.49% |
| 2021-12-31 | $15.49 M | -34.54% |
| 2020-12-31 | $23.67 M | 39.93% |
| 2019-12-31 | $16.91 M | -33.01% |
| 2018-12-31 | $25.25 M | -33.7% |
| 2017-12-31 | $38.08 M | 5.59% |
| 2016-12-31 | $36.07 M | 11.95% |
| 2015-12-31 | $32.22 M | 256.63% |
| 2014-12-31 | $9.03 M | 165.64% |
| 2013-12-31 | $3.4 M | -58.15% |
| 2012-12-31 | $8.12 M | 103.67% |
| 2011-12-31 | $3.99 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | $90.92 B | 218,546.59% | 🇺🇸 USA |
 Merck MRK | $69.04 B | 165,925.39% | 🇺🇸 USA |
 Cytokinetics
CYTK | $1.21 B | 2,811.31% | 🇺🇸 USA |
 AcelRx Pharmaceuticals
ACRX | $6.29 M | -84.87% | 🇺🇸 USA |
 Cara Therapeutics
CARA | $68.75 M | 65.35% | 🇺🇸 USA |